Research Article
Frequency of Hospitalized Infections Is Reduced in Rheumatoid Arthritis Patients Who Received Biological and Targeted Synthetic Disease-Modifying Antirheumatic Drugs after 2010
Figure 1
The number and percentage of hospitalized infections during the treatment with each biological disease-modifying antirheumatic drug (bDMARD)/targeted synthetic disease-modifying antirheumatic drug (tsDMARD). Open bars: the hospitalized infection group. Closed bars: the noninfection group. IFX: infliximab; ETA: etanercept; ADA: adalimumab; TCZ: tocilizumab; ABT: abatacept; GLM: golimumab; CZP: certolizumab pegol; Tofa: tofacitinib.